Metabolic reprogramming of myeloid‑derived suppressor cells in colorectal cancer: Mechanistic insights and immunometabolic targeted rehabilitation (Review)
Authors:
Open Access
- 3 November 2026
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 35 (1) , 1-20
Abstract
Metabolic reprogramming of myeloid‑derived suppressor cells (MDSCs) plays a role in immunotherapy resistance in colorectal cancer (CRC). This metabolic reprogramming appears to be coordinated by oncogenic mutations (such as adenomatous polyposis coli, KRAS and TP53) through a proposed self‑reinforcing ‘mutation‑metabolism‑suppression’ axis. In the present review, four core metabolic pillars sustaining MDSC pathogenicity and the epimetabolic regulation that durably locks them into a suppressive state were examined. Furthermore, two emerging dimensions were highlighted: The spatial metabolic antagonism through which MDSCs may construct a metabolically hostile zone to limit the functional activity of tertiary lymphoid structures, and the remote manipulation of MDSC function by gut and intratumoral microbiota‑derived metabolites. To transcend the limitations of non‑specific myeloid depletion, immunometabolic rehabilitation is proposed as a potentially transformative framework targeting intrinsic metabolic vulnerabilities to functionally reprogram MDSCs from an immunosuppressive to a homeostatic or immunostimulatory phenotype. By integrating emerging spatial omics for precise target validation, artificial intelligence‑guided rational drug design and microbiome modulation, this paradigm provides a strategic roadmap for next‑generation precision immunotherapy, aiming to achieve durable responses across both microsatellite stable and microsatellite instability‑high CRC.Keywords
This publication has 125 references indexed in Scilit:
- Role of tertiary lymphoid structures in the tumour microenvironment and immunotherapy response of renal cell carcinomaClinical and Translational Medicine, 2025
- Deletion of gasdermin D promotes granulocytic myeloid-derived suppressor cell differentiation by decreased release of mitochondrial DNA to promote tumor escapeCancer Immunology, Immunotherapy, 2025
- The Dynamic Changes of Circulating Myeloid-Derived Suppressor Cells (MDSCs) Subsets in Colorectal Cancer Patients Undergoing Oxaliplatin-Based ChemotherapyJournal of Gastrointestinal Cancer, 2025
- Bioconjugated Antibody‐Trojan Immune Converter Enhance Cancer Immunotherapy with Minimized Toxicity by Programmed Two‐Step Immunomodulation of Myeloid CellsAdvanced Healthcare Materials, 2024
- Imaging Mass Cytometry in Immuno-Oncology2023
- Integration of transcriptomics and metabolomics reveals pathways involved in MDSC supernatant attenuation of TGF-β1-induced myofibroblastic differentiation of mesenchymal stem cellsCell and tissue research, 2022
- Detection of Circulating and Tissue Myeloid-Derived Suppressor Cells (MDSC) by Flow Cytometry2021
- Mass spectrometry‐based strategies for single‐cell metabolomicsMass Spectrometry Reviews, 2021
- MicroRNA Expression and Correlation with mRNA Levels of Colorectal Cancer-Related GenesJournal of Gastrointestinal Cancer, 2019
- Fusobacterium nucleatum and colorectal cancer: A mechanistic overviewJournal of Cellular Physiology, 2018